The Goa Institute of Management is conducting a 2-day conclave to study ‘the implications of the patents bill on the pharma industry’ on 20th and 21st August 2005, in Goa.

The Conclave will examine the changing business environment for the Indian Industry due to the introduction of the product patent regime from 1st January 2005.

The theme and the structure of discussions at the Conclave include— Economic, Social and Legal implications of the introduction of TRIPS (Trade-Related aspects of Intellectual Property rights); Impact of the implementation of TRIPS on the business models of Indian majors; Identification of possible business opportunities and the competitive advantage from the changed business scenario; Evolving a policy support framework that would be a guide to decision makers and regulators in specifying guidelines for the sector, informed officials.

The speakers participating conclave include Padmabhushan Dr. Anil Kakodkar, chairman, AEC, Dr. T Ramakrishna, Head CIPRA, NLSIU, S. Ramakrishna, Sr. Director, Corp. Affairs, Pfizer India; Mujumdar, Exec Director, Syngenta; Padmashri Dr. N.R. Madhava Menon, Director, NJA., Dr. Swati Piramal, Director, Nicholas Piramal , Dr. Ajit Dangi, Director General, OPPI, Mr. Ravindra Limaye, VP, Business Development, GSK ,Dr. Girish L. Telang, MD, Roche India.

For Further Information Contact

Anand Kolwalkar: 09890710397, anand04@gim.ac.in
Gary Monteiro: gary04@gim.ac.in